focus -WSS

focus

author：hotspot 2025-10-02 01:09:02 - browse：3316

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： European regulators consider appeal over Amylyx ALS drug

WSS

European regulators consider appeal over Amylyx ALS drug

How medical schools plan to diversify without affirmative action

STAT Readout Newsletter: Today in biotech, life science news

How medical schools plan to diversify without affirmative action

Private equity could exacerbate cardiology's overuse problem, experts fear

Diverse clinical trials: Why aren’t we there yet?

hotspot

focus

explore

Continuity nursing helped my family in our darkest PICU moments

STAT Readout: Today's biotech news includes Sana and Amylyx

Apple is now the first public company to be valued at $3 trillion

How should state employee insurance handle Wegovy?

Affirmative action in medical school literally saved lives

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Medicare details structure of new drug price negotiation program

Peter Marks talks Operation Warp Speed for Rare Diseases

Peter Hotez and the public health issue of online harassment

Telehealth for opioid use disorder is lifesaving

explore

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

How clinical AI models' predictive power can degrade over time

FDA proposes changes to key medical devices approval pathway

How clinical AI models' predictive power can degrade over time

PEPFAR is under serious threat — and so is global health

STAT Readout: Today's biotech news includes Sana and Amylyx

entertainment

explore

knowledge

hotspot